文献速递药物相互作用治疗药物监测与药物基因组学

微剂量探针药物鸡尾酒用于药物转运体与CYP3A临床药物相互作用评估的验证

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
PubMed 文献 · Clin Pharmacol Ther · 2016-12-10

本研究建立含咪达唑仑、达比加群酯、匹伐他汀、瑞舒伐他汀和阿托伐他汀的微剂量鸡尾酒,通过三种抑制剂(利福平、伊曲康唑、克拉霉素)的临床药物相互作用研究验证其临床效用。多数探针药代动力学特征与常规剂量报道或理论预期一致,但达比加群微剂量较常规剂量高约两倍,可用于P-gp最坏情况提示。

要点

  • 微剂量鸡尾酒可同时评估CYP3A及OATP1B、BCRP、P-gp的相互作用影响。
  • 达比加群微剂量较常规剂量高约两倍,可用于P-gp最坏情况提示。
  • 多数探针药代动力学特征与常规剂量或理论预期一致。

核心结论

  • 微剂量鸡尾酒探针可用于临床药物相互作用评估,但达比加群微剂量较常规剂量高约两倍,需注意P-gp最坏情况提示。

研究设计与样本

  • 采用含咪达唑仑、达比加群酯、匹伐他汀、瑞舒伐他汀和阿托伐他汀的微剂量鸡尾酒,与三种抑制剂(利福平、伊曲康唑、克拉霉素)进行临床药物相互作用研究。

主要发现

  • 多数探针在有无抑制剂时的药代动力学特征与常规药理剂量报道或理论预期一致。
  • 达比加群微剂量较常规剂量高约两倍,可用于P-gp最坏情况提示。

临床怎么用

  • 微剂量鸡尾酒可同时评估CYP3A及OATP1B、BCRP、P-gp的相互作用影响。
  • 达比加群微剂量结果可用于提示P-gp最坏情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A microdose cocktail containing midazolam, dabigatran etexilate, pitavastatin, rosuvastatin, and atorvastatin has been established to allow simultaneous assessment of a perpetrator impact on the most common drug metabolizing enzyme, cytochrome P450 (CYP)3A, and the major transporters organic anion-transporting polypeptides (OATP)1B, breast cancer resistance protein (BCRP), and MDR1 P-glycoprotein (P-gp). The clinical utility of these microdose cocktail probe substrates was qualified by conducting clinical drug interaction studies with three inhibitors with different in vitro inhibitory profiles (rifampin, itraconazole, and clarithromycin). Generally, the pharmacokinetic profiles of the probe substrates, in the absence and presence of the inhibitors, were comparable to their reported corresponding pharmacological doses, and/or in agreement with theoretical expectations. The exception was dabigatran, which resulted in an approximately twofold higher magnitude for microdose compared to conventional dosing, and, thus, can be used to flag a worst-case scenario for P-gp. Broader application of the microdose cocktail will facilitate a more comprehensive understanding of the roles of drug transporters in drug disposition and drug interactions.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Prueksaritanont T, Tatosian DA, Chu X, et al. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2016. PMID: 27943276. doi:10.1002/cpt.525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。